Tezspire Shows Positive Phase III Results in Eosinophilic Esophagitis Trial

AstraZeneca and Amgen have reported positive high-level results from the Phase III CROSSING trial of Tezspire (tezepelumab) in patients with eosinophilic esophagitis (EoE). The trial met both co-primary endpoints, evaluating histologic remission and the frequency and severity of dysphagia (difficulty swallowing) compared to placebo. These statistically significant and clinically meaningful improvements were observed at week 24 and sustained through week 52 for both tested doses.

EoE is a chronic, progressive inflammatory disease of the esophagus characterized by inflammation in the esophageal tissue. It can lead to significant swallowing difficulties, food impaction, and esophageal narrowing. Despite available first-line treatments, including dietary modifications and topical corticosteroids, nearly half of patients, including adolescents, do not achieve adequate disease control.

The CROSSING trial was a randomized, double-blind study assessing the efficacy and safety of Tezspire administered subcutaneously every four weeks versus placebo in adults and adolescents with symptomatic and uncontrolled EoE.

Researchers stated that the results reinforce confidence in Tezspire's mechanism of action and its potential as a new treatment approach for EoE, offering the possibility of helping more patients achieve remission and symptom improvement. Full results will be shared with regulatory authorities and at an upcoming medical meeting.